NORML.ORG – Marijuana Use Associated With ‘Superior’ Cognitive Performance In Schizophrenic Patients, Study Says

Toronto, Ontario: Schizophrenic patients with a history of cannabis use demonstrate “superior neurocognitive performance” compared to non-users, according to the findings of a meta-analysis to be published in the journal Schizophrenia Research . Investigators at the University of Toronto, Institute of Medical Sciences, performed a meta-analysis to determine the magnitude of the effect of cannabis consumption on cognition in subjects with schizophrenia. Eight studies met inclusion criteria, yielding a total sample of 942 subjects. Three hundred and fifty six of these participants were cannabis users with schizophrenia, and 586 were patients with no history of cannabis use. Neuropsychological tests were grouped into seven domains: general cognitive ability and intelligence; selective, sustained and divided attention; executive abilities; working memory and learning; retrieval and recognition; receptive and expressive language abilities and visuo-spatial and construction abilities. Authors determined, “[R]elated statistics of differences in performance … all suggest superior cognitive functioning in cannabis-using patients as compared to non-using patient.” Researchers stopped short of attributing subjects’ cannabis use to the improved outcome, noting that patients with superior cognitive skills may simply be more likely to acquire cannabis than subjects with lesser abilities. They wrote: “Given that all studies that met inclusion criteria employed a cross-sectional methodological design, poses a challenge and limits the interpretation of our findings. That is, it is difficult to determine whether it is cannabis itself that triggers alterations in neuropsychological functioning or if drug-using patients represent a subset of the schizophrenia population who exhibit better neurocognitive performance.” Authors concluded, “[C]annabis likely has modest … effects on neurocognitive function in schizophrenia. … Longitudinal designs studying the effects of cannabis abstinence or acute challenges are needed to parse the effects of cannabis per se on cognition in schizophrenia.” For more information, please contact Paul Armentano, NORML Deputy Director: at: paul@norml.org . Full text of the study, ” The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis,” will appear in Schizophrenia Research.

Visit link:
NORML.ORG – Marijuana Use Associated With ‘Superior’ Cognitive Performance In Schizophrenic Patients, Study Says

ATTORNEY ADVERTISEMENT:  This communication or portions thereof may be considered "advertising" as defined by Section 6157(c) of the California Business and Professions Code or within the jurisdiction in which you are viewing this.  Nothing in the discussion above is intended to be a representation or guarantee about the outcome of any legal proceeding in which you may be involved.  By providing the information above in this format, Michel & Associates is not soliciting you to hire it to handle a specific legal matter you may currently have or be anticipating commencing in the future.  Notwithstanding the discussion above, you should not act or refrain from acting on the basis of any content on this site without seeking appropriate legal advice regarding your particular circumstances from an attorney licensed to practice law.  This communication is informational only and does not create an attorney-client relationship between you and Michel & Associates.  Michel & Associates's attorneys are licensed to practice in California, Texas, and the District of Columbia.